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medical conditions, such as diabetes and hypertension, are
managed by physicians who use protocols in daily practice.
These guidelines are often developed by health organizationssh.Edu
ersity Faculty of Medicine.
. All rights reserved.
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lsevierby panels of experts who weigh the evidence of clinical studies,
some of which are randomized. Insurance carriers in the Uni-
ted States often mandate the use of guidelines because it may
mean reduced medical costs. There is an increasing trend to
evaluate physician performance based on utilization of estab-
lished guidelines.
1. Why develop guidelines?
(1) The medical literature may be confusing as to the best
treatment.
(2) There is a large volume of medical literature.
(3) Results of trials often lag beyond treatment
developments.
(4) Some cancers present infrequently, making evaluation
and treatment difﬁcult for the inexperienced clinician.
(5) Experience is invaluable in treating cancer.
Organization Topics Guideline process Where available?
American Society of
Clinical Oncology
(ASCO)
More common
malignancies
management
issues
Consensus committees
of experts
Journal of Clinical
Oncology www.asco.org
National Cancer
Institute (USA)
Controversial or
management
issues in common
malignancies
Consensus committees
of experts with invited
presentations (open
to public)
www.consensus.nih.gov
Consensus publications
mailed to the oncology
community
National Cancer
Center Network
(member NCI-designate
cancer centers)
Most malignancies –
management
from diagnosis to
treatment to follow-up
Expert committees
weighing level of
evidence and producing
consensus opinion, on
an annual basis
www.nccn.org Journal
of the National Cancer
Center Network
European Society of
Medical Oncology
(ESMO)
Major malignancies –
management
from diagnosis to
treatment to follow-up
Working groups of
experts evaluating
level of evidence
and producing
consensus opinion
www.esmo.org/research/
esmo-clinical-practice-guidlines.html
American Cancer
Society
Major malignancies –
screening
Working groups
of experts
www.cancer.org
Cancer Care
Ontario
Major malignancies –
issues
in management
Working groups of
experts (with results
reviewed by membership)
www.cancercare.on.ca
UpToDateª, Inc. Major malignancies –
issues
in management
Invited expert
authors, peer-reviewed
www.uptodate.com
Cochraneª reviews Major malignancies –
issues in management
Volunteers www.cochrane.org
12 K. Kiel(6) Bias is inherent in medical practice.
(7) Guideline development allows a critical review of possi-
ble treatments by experts.
(8) Guideline development allows cost and resource
considerations.
(9) Optimal guidelines will remain current.
(10) Optimal guidelines should be accessible to any interested
party.
Cancer management guidelines should be veriﬁed by clini-
cal trials. However, these are often unavailable. Some cancer
guidelines reﬂect only ‘‘pattern of practice’’, often that of large
institutions with a large experience in those cancers. In every
system, bias is inherent by the choice of participants or trials
selected for inclusion. Guidelines are essentially guides to aid
the physician in choosing the most cost effective course for
an individual with cancer.2. Widely available guideline resources in cancer care
In the higher income countries, several organizations have ta-
ken charge of the guideline process. Table 1 lists several orga-
nizations active in producing guidelines by similar but slightly
different processes. Goals and issues covered may differ based
on the type of organization. Guidelines are often published in
respected medical journals, but are available on their websites.
Other organizations invite experts to publish review articles on
timely topics.All these organizations use experts from different disci-
plines to review medical evidence. The focus of these organi-
zations may be toward recommendations for that modality
(generally medical oncology) practiced by the majority of
members of the sponsoring organization. The NCI chooses
controversial topics and invites investigators to present their
results and data for critical review in multi day meetings in
a public forum. The American Society of Clinical Oncology
(ASCO) develops guidelines created by invited experts both
in the evaluation and in the systemic treatment of common
malignancies. It also works to rapidly evaluate very new
systemic treatments and to advise on their incorporation in
standard practice. The European Society of Medical Oncol-
ogy (ESMO) produces broad guidelines for management
and treatment of malignancies and provides speciﬁc recom-
mendations for many malignancies. Cancer Care Ontario pro-
duces guidelines for its own province in Canada periodically
on speciﬁc topics that affect delivery of care, taking into ac-
count cost-effectiveness. The NCCN has a more expansive
program, with guidelines in evaluation, treatment, follow-up
in all, but the rarest, malignancies. These are produced by
consensus of panels of experts in each type of malignancy
and reviewed annually. NCCN task forces invite their own ex-
perts and outside experts to report on very speciﬁc controver-
sial issues and to publish in the Journal of the National
Comprehensive Cancer Network. These organizations pro-
duce guidelines that are published in peer-review journals
and are accessible on the internet. Many other sources of
guidance are available to many physicians. UpToDate reviews
A 40 year woman ﬁnds a 1 cm hard lump in her right breast. She has a negative family history. Her physical examination is
otherwise negative.
Issue Organization Issue addressed in guideline Issues for resource-limited countries
 Evaluation
 Mammography
 Ultrasound
 MRI
 Type of biopsy
 BRCA testing
Ontario None  Availability of mammography
 Availability of ultrasound
 Availability of BRCA testing
 Availability of MRI
 Skill in core needle biopsies or ﬁne needle aspiration biopsies
by surgeon and pathologist
ASCO None
ESMO Imaging
BRCA testing
Biopsy technique
NCCN Imaging
BRCA testing
Biopsy technique
NCI None
Mammography and ultrasound conﬁrm only a 1 cm speculated mass in the upper outer quadrant of the right breast. Fine needle
aspiration reveals inﬁltrating ductal carcinoma. The patient elects breast conserving surgery.
Issue Organization Issue addressed Issues for resource-limited countries
 Breast conserving surgery
 Axillary evaluation
Ontario Surgical management of the breast  Skill in breast conserving surgery
 Experience in sentinel node biopsy
by surgeon and pathologist
Management of the axilla3
ASCO Sentinel node biopsy4
ESMO Breast conserving surgery
Sentinel node biopsy1
NCCN Surgical management of the breast
Management of the axilla2
NCI Breast conserving surgery5
The patient has 1 cm grade 3 inﬁltrating ductal carcinoma. There is a 1 mm metastasis in one of two sentinel nodes. Hormone
receptors are negative and her2-neu is positive. Margins of resection are negative. There is no lymphovascular invasion. No
ductal carcinoma-in-situ is identiﬁed.
Issue Organization Issue Issues for resource-limited countries
 Tumor markers
 Indications for axillary dissection
 Adjuvant radiotherapy
 Adjuvant chemotherapy
 Adjuvant trastuzimab
Ontario Management of the axilla3  Availability of tumor markers and quality
control
 Type of chemotherapy available
 Availability of trastuzimab
Guideline for taxanes6
Adjuvant radiotherapy7
ASCO Management of the axilla4
Hormone receptor testing8
Her2-neu testing9
ESMO Tumor markers
Management of the axilla
Adjuvant radiation therapy
Adjuvant chemotherapy
Adjuvant trastuzimab1
NCCN Management of the axilla
Adjuvant radiation therapy
Adjuvant systemic therapy10
NCI Adjuvant chemotherapy11
Development of cancer treatment guidelines 13many health issues and is available by individual or institu-
tional subscription, in most US medical school libraries. It
summarizes the literature with recent evidence, and makes
speciﬁc recommendations. The Cochrane Collaboration re-
views health care interventions in cancer and other health is-
sues which have been tested in randomized controlled trials
and publishes summaries. They will include nonrandomized
data when appropriate. Full texts are available by individual
or institutional subscription, and are accessible on PubMed.
There are many review journals that invite experts to publish
a peer reviewed articles on timely topics. These include Oncol-ogyª (Williston Park, NY), Seminars in Oncologyª (Elsevier,
Inc.), Oncology Reviewsª (SpringerLink, Inc.), Critical Re-
view in Oncology/Hematologyª (Elsevier, Inc.), Seminars in
Radiation Oncologyª (Elsevier, Inc.), and American Journal
of Clinical Oncologyª (Wolters Kluwer/Lippincott Williams
& Wilkins, Inc). MedScape Oncologyª (from WebMD)
(www.medscape.com/oncology) provides reviews of major
oncology meetings. In summary, there are many resources
available to the practicing clinician. Many are topic related,
but ESMO and NCCN provide broad, referenced guidelines
in different formats.
14 K. Kiel3. Application of guidelines
An example of how guidelines can be used in a patient example
is shown below. Issues regarding applicability to countries with
limited resources are also listed.
4. Issues in resource-limited countries
Cost-efﬁcient care of cancer is necessary in the global per-
spective. Guidelines provide an opportunity for fair and
cost-efﬁcient care. There are many steps in cancer care that
are necessary for best outcomes. Guideline processes must
recognize that ‘‘shortcuts’’ that may result in short-term cost
savings may also be detrimental in ultimate cost and patient
outcome. For example, limited pathology assessment of hor-
mone receptors may save physician time and laboratory
costs, but treatment with tamoxifen in hormone receptor
negative patients increases ultimate costs and detracts from
cure. Guidelines must be practical. For instance, in the pa-
tient example above, a mammogram and ultrasound are use-
ful when breast conserving surgery is considered. If there are
limited radiation therapy facilities which would not allow for
postlumpectomy radiation, then the information garnered
from an ultrasound is of no use. New expensive drugs and
technologies prevent widespread application of available re-
sources and new drugs. In the example above, trastuzimab
is a very expensive biological agent with high effectiveness
in her2-neu positive breast cancers. If it is not available,
then testing for her2-neu may not be relevant. For the small
breast cancers, controversy in high income countries exists
regarding when adjuvant trastuzimab is appropriate. When
the supply of trastuzumab is limited, the local guiding
authorities must decide for whom trastuzimab is most
appropriate.
The ﬁrst step in developing guidelines should be a state-
ment of expectations. Guidelines should be applicable to
the circumstances of cancer care. Guidelines should be regu-
larly evaluated for relevance and applicability. For instance,
if very early breast cancers are not identiﬁed in the popula-
tion, development and review of guidelines for these patients
waste expert time and energy and resources needed to publish
those guidelines. Guidelines should vary based on the popu-
lation served and the resources available. If radiotherapy
facilities are not widely available, recommendations for breast
conserving therapy is not useful. Mastectomy may be pre-
ferred. However, if patients present with advanced cancers
from fear of mastectomy, guidelines could be produced
encouraging development of new radiation therapy resources
or transfer of patients to those facilities where radiotherapy is
available.
There are regular changes in the paradigmof cancer care, and
guidelines must remain current. For example, in all patients
treated with breast conserving surgery breast irradiation was
recommended, based on an NCI consensus statement. Recent
data suggest that elderly patients with positive hormone
receptors could be treated with tamoxifen and no radiother-
apy.12 Recent data also show that the overall time of breast
radiotherapy can be compressed from 6 to 3 weeks, certainly re-
source-sparing.13,14 Unless there is a regular review of guide-
lines, application of new approaches and treatments may not
occur.5. Summary
Guidelines are useful in managing cancer. Guidelines are only
as good as the individuals involved in the process of develop-
ment and by the method of development. There are many
organizations who have invested heavily in their development.
These have been generally in high income countries where
there are many resources, thus making these not always useful
to cancer practitioners in the lower income countries. Avail-
able guidelines vary widely as to the scope and details of man-
agement. The NCCN and ESMO guidelines are particularly
useful as they cover the scope of management, are evidence
based, and have been developed by experts.References
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